Revisiting the prognostic role of mutations in acute myelogenous leukemia.

INTRODUCTION

Approximately one-third of patients with acute myelogenous leukemia (AML) harbor mutations in the fms-like tyrosine kinase 3 () gene. The features regarding prognostic impact of mutated AML have been widely investigated and debated in the last decades, and the significance of this mutation is constantly evolving.

AREAS COVERED

In this article, the significance of the mutation and various aspects of this mutation are discussed in the light of new understanding and research progress in past years. The recently updated European Leukemia Net (ELN) guidelines are reviewed and discussed, special emphasis given to the the improvement in therapeutic approaches for mutated AML.

EXPERT OPINION

Aspects related to mutated AML include the type of mutation in addition to -internal tandem duplication (ITD) length, location, and allelic ratio. Furthermore, the coexistence of cytogenetic variants and molecular genetic mutations utterly complicate the evaluation of the prognostic impact. In addition, introduction of FLT3 inhibitors and establishment of measurable residual disease (MRD) monitoring have entered the treatment and evaluation armamentarium in the handling of AML patients, resulting in improved prognosis for these patients. However, future research to optimize the treatment of mutated AML is highly desired.